Aug. 14, 2018 /PRNewswire/ --
Array BioPharma Inc. today reported results for its fourth quarter and full year of fiscal 2018 and provided an update on the progress of its key commercial products and clinical development programs.
Array is developing binimetinib in combination with PD-1/PD-L1 checkpoint inhibitors and previously announced separate, strategic collaborations with Bristol-Myers Squibb, Merck and Pfizer.
Each collaboration is pursuing a different rationally designed clinical approach.
Array has granted Ono Pharmaceutical exclusive rights to commercialize both products in Japan and South Korea
Japan's Pharmaceuticals and Medical Devices Agency has accepted the Manufacturing and Marketing Approval applications submitted by Ono Pharmaceutical Co, Ltd.
Aug. 14, 2018 /PRNewswire/ --
Array BioPharma Inc. today reported results for its fourth quarter and full year of fiscal 2018 and provided an update on the progress of its key commercial products and clinical development programs.
Array is developing binimetinib in combination with PD-1/PD-L1 checkpoint inhibitors and previously announced separate, strategic collaborations with Bristol-Myers Squibb, Merck and Pfizer.
Each collaboration is pursuing a different rationally designed clinical approach.
Array has granted Ono Pharmaceutical exclusive rights to commercialize both products in Japan and South Korea
Japan's Pharmaceuticals and Medical Devices Agency has accepted the Manufacturing and Marketing Approval applications submitted by Ono Pharmaceutical Co, Ltd.